Great news for Clovis Oncology, Inc. and GlaxoSmithKline LLC, who have entered into a clinical trial collaboration to evaluate an EGFR targeting combination therapy for non-small cell lung cancer.
The molecules in question are rociletinib and tramtinib, and this will be a Phase 1/2 trial assessing the safety and activity of this combination in patients with EGFR mutant NSCLC who have previously been treated with an EGFR TKI. The trial is scheduled to start within the first half of 2015.
Chris Karlovich, Principal Scientist of Clovis Oncology, will present on rociletinib (CO-1686) at the Skygenix World NSCLC Summit on January 27-28 in Boston, USA.
Read more on the announcement of the collaboration on streetinsider.com